Kailera Therapeutics Reports Q2 2026 Financial Results

What Happened Kailera Therapeutics, Inc. announced on August 12, 2026 that it reported its financial results for the quarter ended June 30, 2026 and furnished an earnings press release. The company filed a Current Report on Form 8-K (Accession 0001193125-26-346919) to disclose the press release; the 8-K was signed by CFO Douglas Pagán.

Key Details

• Date of disclosure: August 12, 2026.
• Reporting period: quarter ended June 30, 2026 (Q2 2026).
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• The company states the information is “furnished” (not “filed”), so it is not subject to Section 18 liability or automatically incorporated by reference into other filings.

Why It Matters This 8-K signals Kailera has provided its quarterly earnings information to the market; investors should review the furnished press release for revenue, profit/loss, cash position, and any management commentary or guidance. Because the release is furnished rather than filed, the company is providing the update without expanding certain legal liabilities—this is a procedural detail but does not change the need to read the earnings content itself for material financial information.